About GENOR-B Company

Our mission Our mission is to be a biopharmaceutical engine for the discovery, research, development, manufacture and commercialization of innovative therapies to benefit patients in China and around the world. Overview Since its establishment in 2007, the Group has focused on becoming an innovative company with innovative drug research and development, pre-clinical research, clinical development, registration and CMC development. Since the successful launch of the “Focus, Optimization, Acceleration and Expansion” development strategy in 2022, and after achieving initial results in 2023, the Group will continue to implement this strategy in 2024, with a view to stable development, efficient operation, and creating opportunities in a challenging economic and industry environment. Focusing on the rapid advancement of core pipelines, the Group further optimized the structure during the reporting period, and successfully transformed the enterprise's asset-light model through various flexible forms of external cooperation. While reducing costs and increasing efficiency, the company continues to promote development at the level of technology, R&D, technology, and management. The Group actively engaged in external cooperation and entered into a license agreement and share purchase agreement with the licensee on August 2, 2024 to jointly develop, use, manufacture, commercialize and otherwise utilize GB261 (CD20/CD3, bispecific antibody), and work together to explore the potential of GB261 (CD20/CD3, bispecific antibody) in autoimmune diseases. This is a recognition of the company's independent research and development capabilities, and it is hoped that this potential BICCD20/CD3 bispecific antibody can be verified by more clinical trial data as soon as possible, and ultimately verify its promising efficacy and good safety. The company expects GB261 (CD20/CD3, bispecific antibody) to become an “innovative therapy serving patients in China and around the world” and supports the company in carrying out its mission. In addition to GB261 (CD20/CD3, bispecific antibody), in terms of expanding foreign cooperation, the Group also signed a technology transfer agreement with China and the US East China in January 2024. According to this agreement, the Group's FGFR2b related molecular sequences, technical data and related IP rights were transferred to the latter. During the reporting period, patients were enrolled in the advanced first-line phase III clinical study of GB491, Lerociclib (, Lerociclib), the core product of the Group, and midterm analysis reached the main end point. The NDA was officially submitted to the National Drug Administration on February 28, 2024, and officially accepted on March 13, 2024. This is another milestone for this core product after GB491, Lerociclib (, Lerociclib) was officially accepted by the NMPA on March 28, 2023 for the marketing of a new drug for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (HR+/HER2-) locally advanced or metastatic breast cancer in combination with fluvix. At the same time, the marketing application for GB491, Lerociclib (, Lerociclib) was also submitted for NDA supplementation in March 2024, and the drug inspection by the Chinese People's Inspection Institute was completed in May 2024. Currently, preparations for the launch of the two new drugs are progressing smoothly. The world's first EGFR/cMET/cMet tri-specific antibody GB263T, developed in-house by the Group, showed promising efficacy in therapeutic doses (1,260-1,680 mg), and also showed good safety characteristics. The updated clinical study data has been accepted by ESMO in 2024. In terms of early research, the Group focuses on molecular research that has the potential to become a global FIC and BIC product and has the greatest potential to produce clinical effects and commercially viable drugs. At present, 5 projects have completed PCC molecule development with the world's first/ best-in-class bis/multispecific antibody projects. The abstracts of the two trispecific antibody molecules independently developed by the company were accepted for publication by AACR in 2024. Among them, the GB268 tri-specific antibody, which is significantly innovative, targets PD-1, CTLA-4, and VEGF, and has the potential to become an upgraded version of an immune checkpoint inhibitor. Shareholders have extensive resources and industry expertise, including global and Chinese biotechnology-focused professional funds, and biopharmaceutical platforms with extensive experience in supporting and developing biopharmaceutical companies. The Group's core management team members have an average of more than 20 years of industry experience, an excellent track record, and a balanced mix of expertise. The goals are clear and the strategy is clear. The company has passionate motivation and deep accumulated professional ability without fear of difficulties. During the reporting period, the company achieved rapid progress on key projects and laid a solid foundation for the continuous achievement of the Group's development goals.